Atousa Hakamifard
- Infectious Diseases top 10%
- Antifungal resistance and susceptibility 15
- COVID-19 Clinical Research Studies 7
-
- Antibiotic Resistance in Bacteria 8
-
- Nosocomial Infections in ICU 5
-
- Bacterial Infections and Vaccines 4
-
- Fungal Infections and Studies 11
- Pneumonia and Respiratory Infections 7
- Pneumocystis jirovecii pneumonia detection and treatment 4
Atousa Hakamifard
54 papers receiving 290 citations
Peers
Comparison fields: 5 of 83
- Applied Microbiology and Biotechnology 17
- Infectious Diseases 126
- Molecular Medicine 27
- Critical Care and Intensive Care Medicine 14
- Microbiology 2
Countries citing papers authored by Atousa Hakamifard
This map shows the geographic impact of Atousa Hakamifard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atousa Hakamifard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atousa Hakamifard more than expected).
Fields of papers citing papers by Atousa Hakamifard
This network shows the impact of papers produced by Atousa Hakamifard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atousa Hakamifard. The network helps show where Atousa Hakamifard may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Atousa Hakamifard, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 15 | |
| 7 | 2023 | 1 | |
| 8 | 2022 | 5 | |
| 9 | 2022 | 7 | |
| 10 | 2022 | 5 | |
| 11 | 2022 | 5 | |
| 12 | 2022 | 6 | |
| 13 | 2022 | 21 | |
| 14 | 2022 | 0 | |
| 15 | 2022 | 2 | |
| 16 | 2021 | 2 | |
| 17 | 2021 | 12 | |
| 18 | 2021 | 5 | |
| 19 | 2020 | 3 | |
| 20 | 2019 | 0 |
About Atousa Hakamifard
Atousa Hakamifard is a scholar working on Applied Microbiology and Biotechnology, Infectious Diseases and Molecular Medicine, having authored 63 papers that have together received 298 indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (15 papers), Fungal Infections and Studies (11 papers), Antibiotic Resistance in Bacteria (8 papers), COVID-19 Clinical Research Studies (7 papers), Pneumonia and Respiratory Infections (7 papers), Nosocomial Infections in ICU (5 papers), Pneumocystis jirovecii pneumonia detection and treatment (4 papers) and Bacterial Infections and Vaccines (4 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (17 citations), Infectious Diseases (126 citations) and Molecular Medicine (27 citations). Atousa Hakamifard has collaborated with scholars based in Iran, United States and Switzerland. Frequent co-authors include Farzin Khorvash, Masoud Mardani, Rasool Soltani, Rasoul Mohammadi, Shervin Shokouhi, Mihan Pourabdollah Toutkaboni, Hamed Fakhim, Shima Aboutalebian, Mohammad Javad Tarrahi and Ali Saffaei.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.